DE69841164D1 - Sphingosin-1-phosphat-lyase polypeptide, polynukleotide und modulierende mitteln, und verfahren zu deren verwendung - Google Patents
Sphingosin-1-phosphat-lyase polypeptide, polynukleotide und modulierende mitteln, und verfahren zu deren verwendungInfo
- Publication number
- DE69841164D1 DE69841164D1 DE69841164T DE69841164T DE69841164D1 DE 69841164 D1 DE69841164 D1 DE 69841164D1 DE 69841164 T DE69841164 T DE 69841164T DE 69841164 T DE69841164 T DE 69841164T DE 69841164 D1 DE69841164 D1 DE 69841164D1
- Authority
- DE
- Germany
- Prior art keywords
- sphingosine
- polynucleotides
- kits
- phosphate lyase
- modulating agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108010014501 sphingosine 1-phosphate lyase (aldolase) Proteins 0.000 title abstract 5
- 239000003795 chemical substances by application Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 102000040430 polynucleotide Human genes 0.000 title abstract 2
- 108091033319 polynucleotide Proteins 0.000 title abstract 2
- 239000002157 polynucleotide Substances 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Cosmetics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/939,309 US6423527B1 (en) | 1997-09-29 | 1997-09-29 | Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
PCT/US1998/020365 WO1999016888A2 (en) | 1997-09-29 | 1998-09-29 | Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69841164D1 true DE69841164D1 (de) | 2009-10-29 |
Family
ID=25472928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69841164T Expired - Lifetime DE69841164D1 (de) | 1997-09-29 | 1998-09-29 | Sphingosin-1-phosphat-lyase polypeptide, polynukleotide und modulierende mitteln, und verfahren zu deren verwendung |
Country Status (9)
Country | Link |
---|---|
US (8) | US6423527B1 (de) |
EP (1) | EP1027443B1 (de) |
JP (1) | JP2001518303A (de) |
AT (1) | ATE443147T1 (de) |
AU (1) | AU9779498A (de) |
CA (1) | CA2305686A1 (de) |
DE (1) | DE69841164D1 (de) |
HK (1) | HK1030018A1 (de) |
WO (1) | WO1999016888A2 (de) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6423527B1 (en) | 1997-09-29 | 2002-07-23 | Children's Hospital Medical Center Of Northern California | Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
US6830881B2 (en) | 1997-09-29 | 2004-12-14 | Children's Hospital & Research Institute At Oakland | Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
JP2002501751A (ja) * | 1998-01-29 | 2002-01-22 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 新規化合物 |
EP1363643A2 (de) * | 2000-12-22 | 2003-11-26 | Medlyte, Inc. | Zusammensetzungen und methoden zur behandlung und vorbeugung von kardiovaskulären erkrankungen und zur identifizierung therapeutischer mittel |
US6692960B2 (en) * | 2001-09-28 | 2004-02-17 | Isis Pharmaceuticals, Inc. | Antisense modulation of sphingosine-1-phosphate lyase expression |
WO2003062390A2 (en) * | 2002-01-17 | 2003-07-31 | Children's Hospital & Research Center At Oakland | Compositions and methods for the modulation of sphingolipid metabolism and/or signaling |
US7674580B2 (en) * | 2002-01-17 | 2010-03-09 | Children's Hospital & Research Center At Oakland | Compositions and methods for the modulation of sphingolipid metabolism and/or signaling |
US20040126834A1 (en) * | 2002-01-17 | 2004-07-01 | Children's Hospital And Research Institute At Oakland | Compositions and methods for the modulation of sphingolipid metabolism and/or signaling |
ES2749400T3 (es) * | 2003-06-06 | 2020-03-20 | Univ Texas | Soluciones de purgado antimicrobianas |
WO2005050222A1 (en) * | 2003-11-19 | 2005-06-02 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of the human sgpl1 gene and protein for neurodegenerative diseases |
US7794713B2 (en) * | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
PT1812797E (pt) * | 2004-10-28 | 2013-05-21 | Lpath Inc | Composições e métodos para o tratamento e prevenção de doenças hiperproliferativas |
WO2006135862A2 (en) * | 2005-06-10 | 2006-12-21 | Children's Hospital And Research Center At Oakland | Immunomodulation by altering sphingosine 1-phosphate lyase (spl) activity |
US7649098B2 (en) | 2006-02-24 | 2010-01-19 | Lexicon Pharmaceuticals, Inc. | Imidazole-based compounds, compositions comprising them and methods of their use |
US20080138334A1 (en) * | 2006-05-31 | 2008-06-12 | Sabbadini Roger A | Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same |
US9274129B2 (en) * | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Methods and reagents for detecting bioactive lipids |
US8796429B2 (en) * | 2006-05-31 | 2014-08-05 | Lpath, Inc. | Bioactive lipid derivatives, and methods of making and using same |
US9274130B2 (en) | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Prevention and treatment of pain using antibodies to lysophosphatidic acid |
US7862812B2 (en) | 2006-05-31 | 2011-01-04 | Lpath, Inc. | Methods for decreasing immune response and treating immune conditions |
CA2667706A1 (en) * | 2006-10-27 | 2008-05-08 | Lpath, Inc. | Compositions and methods for treating ocular diseases and conditions |
RU2460541C2 (ru) | 2006-10-27 | 2012-09-10 | Лпат, Инк. | Композиции и способы связывания сфингозин-1-фосфата |
US20080248032A1 (en) * | 2006-11-21 | 2008-10-09 | Children's Hospital & Research Center At Oakland | Compositions and methods for protection against cardiac and/or central nervous system tissue injury by inhibiting sphingosine-1-phosphate lyase |
TW200848029A (en) | 2007-03-01 | 2008-12-16 | Lexicon Pharmaceuticals Inc | Heterocyclic compounds, compositions comprising them and methods of their use |
TW200920355A (en) * | 2007-09-06 | 2009-05-16 | Lexicon Pharmaceuticals Inc | Compositions and methods for treating immunological and inflammatory diseases and disorders |
US8361465B2 (en) * | 2007-10-26 | 2013-01-29 | Lpath, Inc. | Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents |
US8871202B2 (en) | 2008-10-24 | 2014-10-28 | Lpath, Inc. | Prevention and treatment of pain using antibodies to sphingosine-1-phosphate |
US9200309B2 (en) | 2010-06-28 | 2015-12-01 | Daiichi Sankyo Company, Limited | Method for screening for S1P lyase inhibitors using cultured cells |
US20130259851A1 (en) | 2010-12-01 | 2013-10-03 | Universitat Zurich | Use of prokaryotic sphingosine-1-phosphate lyases and of sphingosine-1-phosphate lyases lacking a transmembrane domain for treating hyperproliferative and other diseases |
US9120835B2 (en) | 2011-06-28 | 2015-09-01 | Daiichi Sankyo Company Limited | Phosphoric acid ester derivatives |
EP3443986A1 (de) * | 2017-08-17 | 2019-02-20 | AC BioScience | Verbesserung des chemotherapiewirkungsgrades durch sphingosin-1-phosphat |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5260288A (en) | 1992-04-03 | 1993-11-09 | The Biomembrane Institute | Method for inhibition of cell motility by sphingosine-1-phosphate and derivatives |
US5376531A (en) * | 1992-09-03 | 1994-12-27 | Northwestern University | Method of detecting cancer |
US5430169A (en) | 1994-02-14 | 1995-07-04 | The United States Of America Represented By The Department Of Health And Human Services | Method for preparation of sphingoid bases |
US6830881B2 (en) | 1997-09-29 | 2004-12-14 | Children's Hospital & Research Institute At Oakland | Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
US6423527B1 (en) | 1997-09-29 | 2002-07-23 | Children's Hospital Medical Center Of Northern California | Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
JP2002501751A (ja) * | 1998-01-29 | 2002-01-22 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 新規化合物 |
WO1999061581A2 (en) | 1998-05-26 | 1999-12-02 | Office Of The Dean Of Research And Graduate Education | Sphingosine kinase, cloning, expression and methods of use |
WO2000070028A1 (en) | 1999-05-13 | 2000-11-23 | Johnson & Johnson Research Pty. Limited | Sphingosine kinase enzyme |
AU1020201A (en) | 1999-10-28 | 2001-05-08 | Warner-Lambert Company | Human sphingosine kinase gene |
WO2001042479A2 (en) | 1999-12-08 | 2001-06-14 | Genoptera, Llc | Insecticide targets and methods of use |
AU2153401A (en) | 1999-12-29 | 2001-07-16 | Aros Applied Biotechnology Aps | Gene expression in biological conditions |
AU2001238283C1 (en) | 2000-02-14 | 2006-02-02 | Curagen Corporation | Sphingosine kinases |
AUPQ744700A0 (en) | 2000-05-11 | 2000-06-01 | Medvet Science Pty. Ltd. | A method of treatment and agents useful for same |
WO2002027028A1 (en) | 2000-09-28 | 2002-04-04 | Atairgin Technologies, Inc. | A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes |
WO2002059376A1 (en) | 2001-01-23 | 2002-08-01 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of human colon cancer |
US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
WO2002085298A2 (en) | 2001-04-20 | 2002-10-31 | Millennium Pharmaceutical, Inc. | Method for detecting breast cancer cells |
US7189507B2 (en) | 2001-06-18 | 2007-03-13 | Pdl Biopharma, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
US20060252035A1 (en) | 2001-08-06 | 2006-11-09 | Lori Friedman | Sphks as modifiers of the p53 pathway and methods of use |
US7674580B2 (en) | 2002-01-17 | 2010-03-09 | Children's Hospital & Research Center At Oakland | Compositions and methods for the modulation of sphingolipid metabolism and/or signaling |
WO2003062390A2 (en) | 2002-01-17 | 2003-07-31 | Children's Hospital & Research Center At Oakland | Compositions and methods for the modulation of sphingolipid metabolism and/or signaling |
-
1997
- 1997-09-29 US US08/939,309 patent/US6423527B1/en not_active Expired - Lifetime
-
1998
- 1998-09-29 AT AT98951982T patent/ATE443147T1/de not_active IP Right Cessation
- 1998-09-29 DE DE69841164T patent/DE69841164D1/de not_active Expired - Lifetime
- 1998-09-29 AU AU97794/98A patent/AU9779498A/en not_active Abandoned
- 1998-09-29 CA CA002305686A patent/CA2305686A1/en not_active Abandoned
- 1998-09-29 EP EP98951982A patent/EP1027443B1/de not_active Expired - Lifetime
- 1998-09-29 JP JP2000513957A patent/JP2001518303A/ja not_active Withdrawn
- 1998-09-29 WO PCT/US1998/020365 patent/WO1999016888A2/en active Application Filing
-
1999
- 1999-07-19 US US09/356,643 patent/US6569666B1/en not_active Expired - Lifetime
-
2001
- 2001-02-09 HK HK01100925.9A patent/HK1030018A1/xx not_active IP Right Cessation
- 2001-05-04 US US09/849,180 patent/US6495359B1/en not_active Expired - Lifetime
-
2002
- 2002-07-15 US US10/197,073 patent/US7041291B2/en not_active Expired - Lifetime
- 2002-10-30 US US10/286,175 patent/US20030059922A1/en not_active Abandoned
-
2004
- 2004-11-01 US US10/979,085 patent/US7262044B2/en not_active Expired - Fee Related
-
2007
- 2007-07-24 US US11/782,458 patent/US20080085995A1/en not_active Abandoned
-
2008
- 2008-12-22 US US12/341,520 patent/US7973143B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20030059922A1 (en) | 2003-03-27 |
US20080085995A1 (en) | 2008-04-10 |
WO1999016888A3 (en) | 1999-06-24 |
CA2305686A1 (en) | 1999-04-08 |
EP1027443B1 (de) | 2009-09-16 |
ATE443147T1 (de) | 2009-10-15 |
US7973143B2 (en) | 2011-07-05 |
US6495359B1 (en) | 2002-12-17 |
US7041291B2 (en) | 2006-05-09 |
EP1027443A2 (de) | 2000-08-16 |
AU9779498A (en) | 1999-04-23 |
US7262044B2 (en) | 2007-08-28 |
US6569666B1 (en) | 2003-05-27 |
US20050221346A1 (en) | 2005-10-06 |
HK1030018A1 (en) | 2001-04-20 |
US6423527B1 (en) | 2002-07-23 |
WO1999016888A2 (en) | 1999-04-08 |
US20090203044A1 (en) | 2009-08-13 |
JP2001518303A (ja) | 2001-10-16 |
US20030166897A1 (en) | 2003-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69841164D1 (de) | Sphingosin-1-phosphat-lyase polypeptide, polynukleotide und modulierende mitteln, und verfahren zu deren verwendung | |
Bielack et al. | Advances in the management of osteosarcoma | |
DE69737684D1 (de) | Präzise wirksamkeitsbestimmungsmethode für wirkstoffe einschliesslich chemotherapeutika | |
DE69632681D1 (de) | Lymphotoxin-alpha/beta komplexe und antikörper gegen den lymphotoxin-beta rezeptor als agenzien gegen tumoren | |
DK2289A (da) | Monoklonale antistoffer samt deres fremstilling og anvendelse | |
DE69738868D1 (de) | Odieren, und deren verwendung zur vorbeugung und zum nachweis von krebs | |
NO980002L (no) | Kaskadepolymerkomplekser, fremgangsmåte for fremstilling, samt farmasöytiske midler inneholdende disse | |
DE69837529D1 (de) | Proteinmarker für lungenkrebs und deren verwendung | |
HK1026739A1 (en) | Methods for detecting cell apoptosis | |
DE69510336D1 (de) | Verfahren zur diagnose von praeklampsie | |
ATE175996T1 (de) | Diagnose von krebs, dessen zellen das am tyrosin phosphorylierte crkl-protein exprimieren | |
ATE350662T1 (de) | Markerproteine für prostatakrebs | |
DE69821246D1 (de) | Testverfahren für collagenpeptid | |
DE69734894D1 (de) | Testverfahren für antifibrotischen wirkstoff | |
DE69839876D1 (de) | Prostat-spezifisches-antigenformen und verfahren zu ihrer bestimmung | |
DE69825629D1 (de) | Säugertier edg-7 rezeptor homologen | |
ATE196688T1 (de) | Verfahren zur vorhersage der therapeutischen antwort eines medikamentes auf einen malignen tumoren | |
DE69209063D1 (de) | Vorprüfung von prostatakrebs durch serum prostatischen spezifischen antigen | |
WO2003062390A3 (en) | Compositions and methods for the modulation of sphingolipid metabolism and/or signaling | |
Chitapanarux et al. | C-type natriuretic peptide induces human colonic myofibroblast relaxation | |
DK1100913T3 (da) | MEKK 1 serin threonin kinaser - interagerende, FHA forkhead associeret domæneprotein 1 (MIF 1) | |
DE59708783D1 (de) | Diagnosehilfe sowie verfahren zum nachweis der trächtigkeit von wiederkäuern | |
DE69815661D1 (de) | Diagnostische verfahren und zusammensetzungen auf basis der verteilung von rad51 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8327 | Change in the person/name/address of the patent owner |
Owner name: CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLA, US |
|
8364 | No opposition during term of opposition |